Spots Global Cancer Trial Database for Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
Official Title: Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP)
Study ID: NCT00808743
Study Description
Brief Summary: Duodenal carcinomas are the leading cause of mortality in patients with Familial Adenomatous Polyposis (FAP) who underwent prophylactic colorectal surgery. The purpose of this study is to determine wether celecoxib combined with ursodeoxycholic acid is an effective chemoprevention strategy to influence the progression of duodenal adenomas to carcinomas in patients with FAP.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Academic Medical Center, Amsterdam, , Netherlands
University Medical Center, Groningen, , Netherlands
Leiden University Medical Center, Leiden, , Netherlands
University Medical Center St. Radboud, Nijmegen, , Netherlands
Erasmus Medical Center, Rotterdam, , Netherlands
Contact Details
Name: Fokko M Nagengast, MD, Ph D
Affiliation: University Medical Center St. Radboud Nijmegen, The Netherlands
Role: PRINCIPAL_INVESTIGATOR
Name: Bjorn WH van Heumen, MD
Affiliation: University Medical Center St. Radboud Nijmegen, The Netherlands
Role: PRINCIPAL_INVESTIGATOR
Name: Wilbert HM Peters, Ph D
Affiliation: University Medical Center St Radboud Nijmegen, The Netherlands
Role: PRINCIPAL_INVESTIGATOR
Name: Ellen Kampman, Ph D
Affiliation: University Medical Center St Radboud Nijmegen, The Netherlands
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
